Fundraising FoxLifeSci Venture Partners
Venture capitalNew York · Series A–Late Stage · 6 people tracked
Also known as LIFESCI VENTURE MANAGEMENT, LLC
Find your way into LifeSci Venture Partners
Each arrow is one introduction. Sign up to fill in the first one.
Sign up to find every way you can get introduced to LifeSci Venture Partners
- Your email: who you already know at LifeSci Venture Partners, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the LifeSci Venture Partners team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
LifeSci Venture Partners backs companies pursuing transformational business models in molecular medicine, healthcare technology, and healthcare delivery. It targets clinical-stage opportunities that have reached proof-of-concept and plan to transition to the public market within 12 to 18 months. The firm partners with entrepreneurs, clinicians, and scientists, offering founder-aligned terms and patient, flexible capital. Beyond funding, portfolio companies gain access to the LifeSci Partners network, a global healthcare consultancy with more than 200 professionals spanning investor relations, communications, executive recruiting, investment banking, event planning, and strategic market analytics, all aimed at accelerating business development and value creation.
Source: firm website, verified Sep 29, 2026.
Team · 6 people
from the firm's website & public directoriesWhat they invest in
from 37 of 52 portfolio companiesBiotech ×31Healthtech ×18Medical Devices ×13Digital Health ×7Deep Tech ×4AI & Machine Learning ×3Consumer ×1Cybersecurity ×1
HQs:United States×28
Who they back
founder profiles across 22 portfolio companiesFounding team size:solo founder×152 founders×64+ founders×1
Where their founders studiedfrom 12 founders with education data
Harvard University ×4
What their founders studiedfrom 13 founders with field-of-study data
Life Sciences ×5Engineering ×4Business & Management ×2Medicine ×2
Investments · 52 tracked
founders shown can be your intro pathBy year:2024 · 12022 · 12021 · 52020 · 32019 · 12017 · 12015 · 113 dated
Achieve is a specialty pharmaceutical company developing and commercializing cytisinicline as a treatment for nicotine dependence, aimed at helping people who smoke quit.
BiotechHealthtechVancouver, B.C., US
Anthony Clarke(Executive Officer)Richard Stewart(Co-founder & Director (former President and CEO))Cindy Jacobs(Executive Officer, Director)inJaime Xinos(Executive Officer)inJohn Bencich(Executive Officer, Director)inAndrew D. Goldberg(Chief Executive Officer & Director)in
Co-investorsvenBio PartnersVivo CapitalFrazier Life Sciences
Beta Bionics develops the iLet Bionic Pancreas System, an insulin delivery device for people with type 1 diabetes aged 6 and older that requires a physician's prescription.
Digital HealthHealthtechMedical DevicesIrvine, US
Edward Damiano(Executive Officer, Director)Sean Saint(President, Chief Executive Officer and Director)inStephen Feider(Chief Financial Officer)inMike Mensinger(Chief Product Officer)inSteven Russell(Chief Medical Officer)inMark Hopman(Chief Commercial Officer)in
Co-investorsOmega FundsRTW Investments L.P.Soleus Capital
Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.
BiotechMedical DevicesBerkeley, US
Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)inMartin Jinek(Co-founder)Andrew May(Executive Officer)
BoardJenny Rooke(Director)inRobert Weisskoff(Director)in
Co-investorsAliment CapitalAvego BioScience CapitalF-Prime CapitalIA Seed VenturesMission Bay CapitalMission Biocapital+3 more
Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer.
AI & Machine LearningBiotechHealthtechMedical DevicesPhiladelphia, US
Osvaldo Flores, Ph.D.(Executive Officer, Director)Douglas Carr(Executive Officer)inBrent Pfeiffenberger(President and Chief Executive Officer)inGregory Russotti(Chief Technology and Manufacturing Officer)Chad Cowan(Chief Scientific Officer)in
BoardToshikazu Ban(Director)
Co-investorsRA CapitalCasdin CapitalVersant Ventures
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)Gary Yeung, CFA(Chief Business Officer)in
BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)
Co-investorsAndreessen HorowitzARCH Venture PartnersColt VenturesEvolution VC PartnersFrazier Life SciencesCity Hill Ventures+1 more
Pyxis Oncology develops antibody-drug conjugates and immunotherapies targeting difficult-to-treat cancers to improve patient outcomes.
BiotechDigital HealthHealthtechMedical DevicesBoston, US
Thomas Civik(Interim Chief Executive Officer, Director)
BoardDavid Steinberg(Executive Officer, Director)inChristoph Westphal(Director)Geeta Vemuri(Director)inJak Knowles(Director)John Flavin(Director)
Co-investorsAgent CapitalLongwood FundPfizer Venture InvestmentsRA CapitalTrans-Pacific Technology FundRTW Investments L.P.
BiotechTel Aviv
Shmuel Cabilly(Director)June Almenoff(Executive Officer)Ofer Tsimchi(Director)Rick D Scruggs(Executive Officer, Director)Nicolas Weinstein(Director)Alla Felder(Director)
PartnerPaul Yook· solo GP
Co-investorsHEALTHCARE ROYALTY PARTNERS
Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells.
BiotechDeep TechMedical DevicesSouth San Francisco, US
Tim Lu(Co-Founder and Chief Executive Officer)inPhilip Lee(Executive Officer)inKanya Rajangam(President, Head of Research & Development and Chief Medical Officer)inYvonne Li(Executive Officer)inJames Collins(Director)
BoardDonald Tang(Director)
Co-investorsEvolution VC PartnersFlucas VenturesLifeforce CapitalLux CapitalMenlo VenturesNew Enterprise Associates (NEA)+12 more
Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.
BiotechHealthtechWest Hartford, US
Reid Waldman(Chief Executive Officer and Board Member)inTim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)
Co-investorsLongitude CapitalConnecticut InnovationsOUP (Osage University Partners)SR One Capital Managementabrdn plcInvus
Orasis is a pharmaceutical company developing drugs for the eye, operating in the ophthalmology and eyecare space.
BiotechHealthtechMedical Devices
Co-investorsArboretum VenturesMaverick Ventures IsraelVisionary VenturesCatalio Capital ManagementJohnson & Johnson Innovation – JJDCSequoia Capital+1 more
Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureForesite CapitalFrazier Life SciencesScion Life SciencesThe Innovation SpacevenBio Partners+1 more
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)
Co-investorsAlta PartnersNew Enterprise Associates (NEA)RiverVest Venture PartnersSamsara BioCapitalRoche Venture Fund
Develops novel therapies for rare pediatric neurodegenerative diseases.
Co-investorsAsahi Kasei Corporate Venture CapitalLG Technology VenturesPappas Capital
Ambros Therapeutics is a clinical-stage biotechnology company developing medicines for diseases with high unmet medical need, with a lead program targeting complex regional pain syndrome type 1 (CRPS-1), a rare condition typically following limb injury.
BiotechSan Diego, US
Joseph (Jay) Hagan(President and Chief Executive Officer)
Co-investorsRA CapitalBAM ElevateJanus Henderson InvestorsPatient Square Capital
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalPontifax Venture CapitalAmzak HealthDelos Capital+8 more
A biotechnology company developing new therapies for patients with high unmet medical needs.
Biotech
Co-investorsDolby Family VenturesSofinnova VenturesThe W FundCommodore CapitalFranklin TempletonLigand Pharmaceuticals+5 more
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)inGreg Bell(Executive Officer)
Co-investorsAlpha Wave GlobalBioBritvenBio PartnersJanus Henderson InvestorsREDMILESamsara BioCapital+2 more
Augmedix builds AI-driven documentation technology for clinicians, aiming to reduce time spent on technology so providers can focus on patient care.
AI & Machine LearningDigital HealthHealthtechSan Francisco, US
Ian Shakil(Executive Officer, Director)inPelu Tran(Cofounder)inEmmanuel Krakaris(Executive Officer, Director)inPaul Ginocchio(Executive Officer)inSandra Breber(Executive Officer)inJoseph Marks(Director)
Co-investorsDCM VenturesEvolution VC PartnersGreat Oaks Venture CapitalOVO FundSand Hill AngelsDCM+1 more
Averto Medical is developing a medical device intended to improve care for patients undergoing colorectal surgery.
HealthtechMedical Devices
Biolinq develops glucose-sensing technology based on micro-array biosensors for metabolic health monitoring, including continuous glucose monitoring.
BiotechDigital HealthHardwareHealthtechMedical DevicesSan Diego, US
Jared Tangney(Co-founder)inRich Yang(Co-founder)inEdward Kliphuis(Director)
BoardDaniel Bradbury(Director)inLana Ghanem(Director)
Co-investorsAlpha Wave GlobalRiverVest Venture PartnersAble PartnersAphelion CapitalAverin CapitalBeyond Capital+7 more
Bright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform.
BiotechDeep TechHealthtechNew York, US
Alan Kozikowski(Executive Officer, Director)inIan McDonaldRyan Cheung(Chief Financial Officer)JAN PEDERSEN(Chief Science Officer)Gideon Shapiro(Executive Officer)Revati Sheeniwas(Executive Officer)
Co-investorsPalo Santo VCPsyMed Ventures
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalOrbiMedSamsara BioCapitalTCG CrossoverThird Rock VenturesvenBio Partners+1 more
Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.
BiotechHealthtech
Co-investorsAdvent Life SciencesEcoR1 CapitalForesite CapitalMedicxiOberland CapitalScion Life Sciences+3 more
BiotechCambridge, US
Chad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)
BoardMartin Murphy(Director)
Co-investorsBain Capital Life SciencesCasdin CapitalVenrock Healthcare Capital Partners
Cannabis retailer operating dispensaries across Maryland, New York, Ohio, and Pennsylvania.
ConsumerRetail Tech
Co-investorsArtemis Growth Partners
Crescent Biopharma is an oncology-focused biopharmaceutical company developing cancer treatments aimed at establishing new standards of care for patients living with cancer.
Biotech
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPHBM Healthcare InvestmentsHBM PartnersKhosla Ventures+13 more
Company whose formation and launch the LifeSci team supported.
BiotechHealthtechSummit, US
Gregory Mayes(Executive Officer, Director, Promoter)Jouko Isojarvi(Executive Officer)Stephen D. Collins(Director)Warren Lammert(Director)inOrrin Devinsky(Director)
BoardGerry Brunk(Director)in
PartnerPaul Yook· solo GP
Co-investorsLumira VenturesRed Tree Venture
Iridia develops Molecular Avatar Technology that embeds unalterable molecular identities and custom data (text, image, audio, or video) into physical products and materials such as paints, coatings, plastics, and liquids.
BiotechDeep TechNew Materials
PartnerPaul Yook· solo GP
Co-investorsConnecticut InnovationsDuke Capital PartnersLongley CapitalWestern Digital CapitalPrime Movers Lab
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Co-investorsage1EcoR1 CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Vivo Capital+8 more
Minerva Labs was an Israeli endpoint security company whose anti-evasion platform prevented malware by simulating hostile environments to deter evasive threats.
Cybersecurity
Co-investorsAccelmed PartnersAmplify PartnersSaints CapitalStageOne VenturesWebb Investment NetworkGlencrest Group
A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.
Biotech
Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in
Co-investorsNextech InvestThird Rock VenturesAlexandriaCasdin CapitalCreacion VenturesGoldman Sachs+3 more
Acquired by Genmab in April 2024.
Co-investorsB Capital GroupB4 CapitalHongShan Capital GroupLAVLilly Asia VenturesLYFE Capital+2 more
.jpeg){kind=logo}
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
BoardAaron Royston(Director)in
Co-investorsSamsara BioCapitalScion Life SciencesSofinnova VenturesTCG CrossovervenBio PartnersVersant Ventures+2 more
Rocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders.
BiotechDigital HealthMedical Devices
Gaurav Shah(Co-founder & Chief Executive Officer)in
BoardRoderick Wong(Director)inNaveen Yalamanchi(Director)in
Co-investorsAvoro Capital AdvisorsBroadview VenturesCivilization Ventures Management, LlcFrazier Life SciencesRTW Investments L.P.
Science37 operates a decentralized clinical trial platform supported by a network of medical directors across specialties including cardiology, neurology, psychiatry, pediatrics, and internal medicine.
BiotechDigital HealthHealthtechMedical Devices
Tyler Van Horn(Chief Executive Officer)inDebra Weinstein(Chief Medical Officer)in
Co-investorsGlynn Capital ManagementGV (Google Ventures)Lux CapitalSanofi VenturesInertia VenturesREDMILE
Vyne Therapeutics is a biopharmaceutical company developing treatments for Graves' disease and thyroid eye disease (TED).
Biotech
Co-investorsF-Prime Capital
WorkStep (WorkHound) is an AI-powered employee engagement platform for frontline and distributed workforces, offering surveys, AI-generated responses to feedback, targeted communications, and predictive insights.
AI & Machine LearningHR TechSaaSChattanooga, US
Max Farrell(CEO)inAndrew Kirpalani(Executive Officer, Director)Elizabeth Engel(Director)
Co-investorsDivide by ZeroDynamo VenturesGrand VenturesLevel EquityLightyearSpringTime Ventures+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Dodo OmniDataAttuneBionomicsCala HealthCybinLarondeMana TherapeuticsNovusOmega TherapeuticsOrasisOrphai TherapeuticsThar PharmaceuticalsViractaYarrow Biosciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 13
10 IPOs · 3 acquisitions · showing 11Achieve Life SciencesNASDAQ: ACHVBeta Bionics, IncNASDAQ: BBNXCaribou BiosciencesNASDAQ: CRBUCentury Therapeutics, Inc.NASDAQ: IPSCErascaNASDAQ: ERASPyxis OncologyNASDAQ: PYXSRedHill Biopharma LtdNASDAQ: RDHLSenti BiosciencesNASDAQ: SNTIVeradermicsNYSE: MANEAmbros Therapeuticsacq. by Werewolf TherapeuticsMinerva Labsacq. by Rapid7
Portfolio news
latest coverage across their companiesCrescent Biopharma · globenewswire.com · Sep 3, 2026
Achieve Life Sciences · finance.yahoo.com · Apr 16, 2026
Athira · geekwire.com · Dec 18, 2025
Ambros Therapeutics · ambrostherapeutics.com · Oct 3, 2025
Frequently asked questions
- How many investments has LifeSci Venture Partners made?
- LifeSci Venture Partners has 52 tracked investments, 13 of which have exited.
- What stage does LifeSci Venture Partners invest at?
- LifeSci Venture Partners invests at the Series A, Series B, Series C, Late Stage stages.
- What sectors does LifeSci Venture Partners focus on?
- LifeSci Venture Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is LifeSci Venture Partners located?
- LifeSci Venture Partners is headquartered in New York, US.
- Does LifeSci Venture Partners lead rounds?
- LifeSci Venture Partners typically participates in rounds rather than leading them.
- Who does LifeSci Venture Partners co-invest with?
- LifeSci Venture Partners most often shares deals with venBio Partners, RA Capital, Foresite Capital, among 113 tracked co-investors.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Avego is a healthcare-focused investment firm that partners with entrepreneurs and management teams across private and public companies developing products and services throughout the healthcare continuum. Its Avego BioScience Capital strategy focuses on mid-to-late stage venture financings for biotech companies.